DRAVP ID  DRAVPe00423

Peptide Name   IBP21

Sequence  SVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK

Sequence Length  37

UniProt ID  No entry found

Source  Synthetic construct(derived from HR2 region of SARS-CoV-2)

Target Organism  SARS-CoV-2

Assay 

Activity 

• [Ref.34057039]SARS-CoV-2:inhibition of SARS-CoV-2 S protein-mediated cell-cell fusion(IC50=7.5 nM);inhibition of pseudovirus infections in 293T/ACE2 cells(IC50=191.4 nM);inhibition of pseudovirus infections in Huh-7 cells(IC50=126.65 nM).

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity  No cytotoxicity information found in the reference(s) presented

Binding Target  membrane

Mechanism  Peptides derived from HR2 sequences of viral fusion proteins, including the S protein of emerging CoVs, can competitively bind to the HR1 domain and block the formation of the viral 6-HB core, thereby inhibiting infection of the virus from which they were derived.

PDB ID  None

Predicted Structure Download  No predicted structure available

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  C16(palmitic acid)

Other Modification  None

Stereochemistry  L

Literature 1

Title   Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.

Pubmed ID   34057039

Reference   Emerg Microbes Infect. 2021 Dec;10(1):1227-1240.

Author   Yu D, Zhu Y, Jiao T, Wu T, Xiao X, Qin B, Chong H, Lei X, Ren L, Cui S, Wang J, He Y.

DOI   10.1080/22221751.2021.1937329